[go: up one dir, main page]

CA2377999A1 - Compositions et methodes permettant d'augmenter les taux de hdl cholesterol - Google Patents

Compositions et methodes permettant d'augmenter les taux de hdl cholesterol Download PDF

Info

Publication number
CA2377999A1
CA2377999A1 CA002377999A CA2377999A CA2377999A1 CA 2377999 A1 CA2377999 A1 CA 2377999A1 CA 002377999 A CA002377999 A CA 002377999A CA 2377999 A CA2377999 A CA 2377999A CA 2377999 A1 CA2377999 A1 CA 2377999A1
Authority
CA
Canada
Prior art keywords
accordance
alkyl
group
lxr agonist
lxr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002377999A
Other languages
English (en)
Inventor
Bei Shan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tularik Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2377999A1 publication Critical patent/CA2377999A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des agonistes des récepteurs LXR et des méthodes d'utilisation de ces agonistes pour augmenter les taux plasmatiques de HDL (lipoprotéines de haute densité) chez des mammifères et pour prévenir, stopper ou ralentir la progression de maladies cardio-vasculaires athérosclérotiques et des états pathologiques associés.
CA002377999A 1999-07-08 2000-07-07 Compositions et methodes permettant d'augmenter les taux de hdl cholesterol Abandoned CA2377999A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14299499P 1999-07-08 1999-07-08
US60/142,994 1999-07-08
US61213500A 2000-07-07 2000-07-07
PCT/US2000/018533 WO2001003705A1 (fr) 1999-07-08 2000-07-07 Compositions et methodes permettant d'augmenter les taux de hdl cholesterol
US09/612,135 2000-07-07

Publications (1)

Publication Number Publication Date
CA2377999A1 true CA2377999A1 (fr) 2001-01-18

Family

ID=26840588

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002377999A Abandoned CA2377999A1 (fr) 1999-07-08 2000-07-07 Compositions et methodes permettant d'augmenter les taux de hdl cholesterol

Country Status (5)

Country Link
EP (1) EP1212065A4 (fr)
JP (1) JP2004500332A (fr)
AU (1) AU6074700A (fr)
CA (1) CA2377999A1 (fr)
WO (1) WO2001003705A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8076376B2 (en) 2005-07-22 2011-12-13 Powers Jay P Aniline sulfonamide derivatives and their uses

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030153541A1 (en) * 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
AU1291901A (en) * 1999-09-01 2001-03-26 University Of British Columbia, The Compositions and methods for modulating hdl cholesterol and triglyceride levels
US20020048572A1 (en) * 2000-05-03 2002-04-25 Bei Shan Treatment of hypertriglyceridemia and other conditions using LXR modulators
CA2435067C (fr) 2001-01-26 2011-11-15 Chugai Seiyaku Kabushiki Kaisha Inhibiteurs de malonyl-coa decarboxylase utiles comme modulateurs metaboliques
JP4267920B2 (ja) * 2001-01-26 2009-05-27 中外製薬株式会社 代謝調節剤として有用なマロニル−ＣｏＡ脱炭酸酵素阻害剤
EP1353662B1 (fr) * 2001-01-26 2007-04-18 Chugai Seiyaku Kabushiki Kaisha Procedes relatifs au traitement de maladies par le biais d'inhibiteurs de malonyl-coa decarboxylase
ES2353686T3 (es) 2001-02-20 2011-03-04 Chugai Seiyaku Kabushiki Kaisha Azoles como inhibidores de la malonil-coa-descarboxilasa útiles como moduladores metabólicos.
US7709510B2 (en) 2001-02-20 2010-05-04 Chugai Seiyaku Kabushiki Kaisha Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
WO2002077229A2 (fr) * 2001-03-01 2002-10-03 Lion Bioscience Ag Nouveaux cofacteurs du recepteur alpha x du foie et techniques d'utilisation
CA2444028A1 (fr) 2001-04-18 2002-10-31 Genzyme Corporation Methodes pour traiter le syndrome x avec des polyamines aliphatiques
EP1285662A1 (fr) * 2001-08-20 2003-02-26 ZLB Bioplasma AG Lipoprotéine à haute densité reconstituée utilisée pour le traitement d' attaques et des conditions d'ischémie
CA2457840C (fr) 2001-08-20 2011-10-11 Zlb Bioplasma Ag Lipoproteines de haute densite (hdl) pour le traitement des accidents vasculaires cerebraux (avc) et autres evenements ischemiques
US6924311B2 (en) * 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
GB2381866A (en) * 2001-11-12 2003-05-14 Karobio Ab Assays for liver X receptor (LXR) modulators
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
CA2469435A1 (fr) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Modulateurs de lxr
AU2003220521A1 (en) * 2002-03-27 2003-10-13 Smithkline Beecham Corporation Methods of treatment with lxr modulators
WO2003090869A1 (fr) * 2002-04-23 2003-11-06 Chugai Seiyaku Kabushiki Kaisha Modulateurs de lxr
WO2003090732A1 (fr) * 2002-04-23 2003-11-06 Chugai Seiyaku Kabushiki Kaisha Modulateurs lxr pour le traitement des maladies cardio-vasculaires
GB0316237D0 (en) * 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
GB0316232D0 (en) 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
JP2006528200A (ja) * 2003-07-22 2006-12-14 グラクソ　グループ　リミテッド Ｌｘｒアゴニストを用いる治療方法
ES2353306T3 (es) 2003-08-01 2011-03-01 Chugai Seiyaku Kabushiki Kaisha Compuestos heterocíclicos útiles como inhibidores de la malonil-coa-descarboxilasa.
DE602004009582T2 (de) 2003-08-01 2009-01-02 Chugai Seiyaku K.K. Cyanoamid-verbindungen als nützliche malonyl-coa decarboxylase-hemmer
ATE536872T1 (de) 2003-08-01 2011-12-15 Chugai Pharmaceutical Co Ltd Azol-verbindungen auf cyanoguanidin-basis als malonyl-coa decarboxylase-hemmer
US7449482B2 (en) 2003-08-01 2008-11-11 Chugai Seiyaku Kabushiki Kaisha Piperidine compounds useful as malonyl-CoA decarboxylase inhibitors
SE0500055D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
SE0500056D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 4
CA2592771A1 (fr) * 2005-01-10 2006-07-13 Astrazeneca Ab Derives de 1,1-dioxydes d'isothiazol-3(2h)-one utilises comme modulateurs du recepteur x du foie
WO2006073364A1 (fr) * 2005-01-10 2006-07-13 Astrazeneca Ab Derives non aniliques d'isothiazol-3(2h)-thione 1,1-dioxides servant de modulateurs de recepteurs nucleaires hepatiques
US8569352B2 (en) 2005-06-27 2013-10-29 Exelixis Patent Company Llc Imidazole based LXR modulators
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
RU2013115395A (ru) 2010-09-07 2014-10-20 СНУ Ар энд ДиБи ФАУНДЕЙШН Сестертерпеновое соединение и его применение
AR088728A1 (es) 2011-03-25 2014-07-02 Bristol Myers Squibb Co Moduladores de lxr como prodroga de imidazol
CN105250253B (zh) * 2015-10-30 2018-06-26 黄恺 T0901317作为parp1抑制剂的应用
CN109071516B (zh) 2015-12-15 2021-08-31 阿斯利康(瑞典)有限公司 新颖的化合物
WO2018229155A1 (fr) 2017-06-14 2018-12-20 Astrazeneca Ab 2,3-dihydroisoindole-1-carboxamides utiles en tant que modulateurs de ror-gamma

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES442992A1 (es) * 1974-12-02 1977-08-01 Scherico Ltd Un procedimiento para preparar 2-anilino-oxazolinas.
WO2000034461A2 (fr) * 1998-12-10 2000-06-15 Board Of Regents, The University Of Texas System Compositions et techniques de modulation du metabolisme du cholesterol
US6316503B1 (en) * 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
SG121852A1 (en) * 1999-06-18 2006-05-26 Cv Therapeutics Inc Compositions and methods for increasing cholesterol efflux and raising hdl using atp binding cassette transporter protein abc1

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8076376B2 (en) 2005-07-22 2011-12-13 Powers Jay P Aniline sulfonamide derivatives and their uses

Also Published As

Publication number Publication date
JP2004500332A (ja) 2004-01-08
AU6074700A (en) 2001-01-30
WO2001003705A1 (fr) 2001-01-18
EP1212065A4 (fr) 2004-02-11
EP1212065A1 (fr) 2002-06-12

Similar Documents

Publication Publication Date Title
CA2377999A1 (fr) Compositions et methodes permettant d'augmenter les taux de hdl cholesterol
Kavanagh et al. Pharmaceutical cocrystals: from serendipity to design to application
Almansa et al. Co-Crystal of Tramadol hydrochloride–Celecoxib (CTC): a novel API–API co-crystal for the treatment of pain
Atanasov et al. Honokiol: a non-adipogenic PPARγ agonist from nature
ES2853485T3 (es) Derivado de urea como compuesto inhibidor de Trk
US6180660B1 (en) Cholesterol-lowering therapy
WO2001064646A2 (fr) Hydrazones et analogues utilises comme agents reducteurs de cholesterol
AU2007230991A1 (en) Compounds and methods for treatment of disorders associated with ER stress
Haggie et al. SLC26A3 inhibitor identified in small molecule screen blocks colonic fluid absorption and reduces constipation
PT1302461E (pt) Inibidores de produção de tnf-alpha
CA2367595A1 (fr) Modulateurs du lxr
US6673831B1 (en) Combination therapy for reducing the risks associated with cardiovascular disease
WO2006001877A2 (fr) Composition pharmaceutique et methode de traitement de troubles neurodegeneratifs
Helmstadter et al. Second-generation dual FXR/sEH modulators with optimized pharmacokinetics
Chen et al. A combined bioinformatics and chemoinformatics approach for developing asymmetric bivalent AMPA receptor positive allosteric modulators as neuroprotective agents
Prevost et al. Identification of cinnamic acid derivatives as novel antagonists of the prokaryotic proton-gated ion channel GLIC
US20080103209A1 (en) Compounds And Methods For Treating Non-Inflammatory Pain Using Ppar Alpha Agonists
RS63534B1 (sr) Farmaceutske kombinacije koje sadrže inhibitor histon deacetilaze i inhibitor bcl-2 i postupci za njihovu upotrebu
Al-Wahaibi et al. Probing the effect of halogen substituents (Br, Cl, and F) on the non-covalent interactions in 1-(adamantan-1-yl)-3-arylthiourea derivatives: A theoretical study
Anand et al. Prediction of activity spectra of substances assisted prediction of biological activity spectra of potential anti-Alzheimer’s phytoconstituents
Malawska et al. Investigation into new anticonvulsant derivatives of α-substituted N-benzylamides of γ-hydroxy-and γ-acetoxybutyric acid. Part 5: Search for new anticonvulsant compounds
Dawson et al. Adamantyl-substituted retinoid-derived molecules that interact with the orphan nuclear receptor small heterodimer partner: effects of replacing the 1-adamantyl or hydroxyl group on inhibition of cancer cell growth, induction of cancer cell apoptosis, and inhibition of SRC homology 2 domain-containing protein tyrosine phosphatase-2 activity
Gabriele et al. Methanethiosulfonate derivatives as ligands of the STAT3-SH2 domain
AU9115398A (en) Cholesterol-lowering therapy
Anchoori et al. Novel microtubule-interacting phenoxy pyridine and phenyl sulfanyl pyridine analogues for cancer therapy

Legal Events

Date Code Title Description
FZDE Dead